JPRN-jRCTs031180181进行中（未招募）3 期
JCOG1510: A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus - TRIANgLE
DAIKO Hiroyuki0 个研究点目标入组 230 人开始时间: 2019年3月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1) Histologically proven squamous cell carcinoma, adenosquamous carcinoma or basaloid cell carcinoma by endoscopic biopsy for the primary esophageal tumor.
- •2) Primary tumor located in thoracic esophagus (the UICC-TNM 7th edition). Tumor invading cervical or abdominal esophagus with indication of definitive radiation therapy and accessory lesions with indication of EMR are eligible.
- •3) Unresectable esophageal cancer based on cervical to abdominal contrast enhanced CT to fulfill either following A) or B), and patients with both bleeding and symptom related to airway constriction which are induced by esophageal hiatus, esophagorespiratory fistula, esophagomediastinal fistula, or artery invasion are ineligible.
- •A) cT4b or cT3 that may invade adjacent organs in accordance with UICC-TNM 7th edition and Japanese Classification of Esophageal Cancer 11th edition.
- •B) Other adjacent organs except esophagus are or may be invaded by regional lymph nodes or supraclavicular lymph nodes metastases, and patients with both unresectabel supraclavicular lymph nodes and celiac artery lymph nodes metastases.
- •4) No distant metastases except supraclavicular lymph nodes metastases in accordance with cervical to abdominal contrast enhanced CT.
- •5) Diagnosed by radio oncologists before register as a candidate of definitive radiotherapy in 60 Gy within the dose constraints of other organs. CT for treatment planning before register is not mandatory.
- •6) Aged 20 to 75 years old.
- •7) ECOG Performance status 0 or 1.
- •8) Measurable lesions not required.
- •9) No prior treatment for esophageal cancer except endoscopic resection.
- •10) No prior chemotherapy and radiotherapy for any cancer.
- •11) Sufficient organ functions
- •12) Agreement with surgical procedure as protocol treatment if R0 esophagectomy is judged as possible.
- •13) Written informed consent.
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies.
- •2) Prior surgery for head and neck superficial carcinoma within 5 years.
- •3) Diagnosed with active infectious disease requiring systemic treatment by imaging or bacteriological inspections, and body temperature >= 38 degrees Celsius.
- •4) Positive for HBs antigen or HIV antibody.
- •5) Pregnancy, possible pregnancy, within 28 days after delivery or breast-feeding. Male subjects who want pregnancy of their partner.
- •6) Psychological disorder difficult to participate in this clinical study.
- •7) Receiving continuous systemic corticosteroid or immunosuppressant treatment.
- •8) Under treatment by flucytosine, phenytoin, or warfarin potassium.
- •9) Previous history of allergy to iodine.
- •10) Diabetes mellitus uncontrollable with continuous use of insulin or hypoglycemic agents.
- •11) Severe emphysema or pulmonary fibrosis based on chest CT.
- •12) Uncontrolled arterial hypertension.
- •13) History of unstable angina pectoris with new onset or exacerbation within three weeks or myocardial infarction within six months before registration.
- •14) Uncontrolled valvular disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy.
研究者
相似试验
招募中
3 期
A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE)locally advanced unresectable squamous cell carcinoma of the thoracic esophagusJPRN-UMIN000031165Japan Clinical Oncology Group (JCOG)230
招募中
3 期
JCOG2103: Randomized phase III study comparing systemic therapy and debulking surgery consisting of primary tumor resection with systemic therapy alone for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural disseminatioJPRN-jRCTs031220666WATANABE Shun-ichi170
招募中
2 期
JCOG2203: A randomized controlled phase II/III trial of neoadjuvant chemotherapy for Japanese patients with esophagogastric junction adenocarcinomaJPRN-jRCTs031230182KUROKAWA Yukinori460
招募中
3 期
JCOG1901: An intergroup phase III study of combination therapy with everolimus and lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumorJPRN-jRCT1031200023MIZUNO Nobumasa250
进行中（未招募）
3 期
JCOG1109: A randomized controlled phase III comparing CF versus DCF versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancerclinical stage IB/II/III thoracic esophageal cancerJPRN-jRCTs031180202Kato Ken600